TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06218459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oldpain2go®
Description: OldPain2Go® is a non-medical intervention for the treatment of chronic pain conditions including, but not limited to Chronic Low Back Pain. The underlying premise is rooted in the biopsychosocial model of pain, where the cause of ongoing pain and the development of chronicity, is believed to lie beyond simple tissue damage, injury or malfunction. The intervention draws upon subconscious communication as a means to help patients to re-frame their pain as less threatening and remove old, out of date, pain messages that no longer serve a purpose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jacobson's progressive relaxation
Description: Jacobson's progressive relaxation is a technique commonly used for eliciting the relaxation response and relieving muscular tension. It involves sequentially relaxing various muscle groups, often starting at the head and moving down the body to the feet.
Study: NCT04660929

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-PD antibody
Study: NCT06140147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolised reduction of non-resuscitation fluids
Description: Maintenance fluid: discontinued if cumulative fluid balance is positive and patient is not dehydrated Intravenous fluid and enteral water: as needed to correct electrolyte disturbances Enteral nutrition (at least 2 kcal/ml): per local practice Glucose (conc. ≥20%, dose ≤1g/kg/day): may be used as nutrition if enteral feeding not tolerated starting 72h after inclusion. May be started earlier in patients with insulin-dependent diabetes or risk of hypoglycemia per local practice Parenteral nutrition: per local practice Intravenous medications: concentrated according to a predefined protocol Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids so the total dose of fluids covers the daily need of water (about 1ml/kg/h)

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~Maintenance fluids (crystalloids and/or glucose and/or enteral water): given at a dose of 1 ml/kg/h unless local protocol states otherwise Glucose: used at maximal concentration of 10% unless local protocol states otherwise.~Medications: concentrated per local protocol
Study: NCT04742205

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid 500 MG
Description: Loading dose of trial (1g of tranexamic acid in 10ml) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial mixed in 500ml sodium chloride 0.9% is given over 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 500 MG
Description: Loading dose of trial (1g of tranexamic acid in 10ml) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial mixed in 500ml sodium chloride 0.9% is given over 8 hours
Study: NCT05537467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Patients randomized to the music group will listen to upbeat music using headphones.
Study: NCT05133479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Know! small-group or TierL 2 Intervention
Description: Let's Know! is an 22-week intervention spanning 1 school year. Each week features 4-5, 30 minute lessons targeting lower-level and higher-level language skills. There are 2 narrative and 2 expository units. Within units, instructors and children progress through specific types of lessons to meet language-focused learning objectives. Lesson types include (a) Read to Me, designed to engage children with text and promote discussion, inferential language, and comprehension monitoring, (b) Words to Know, designed to unit vocabulary, (c) Integration, to teach and practice retelling, inferencing and comprehension monitoring (d) Show Me What You Know, instructors administer CAMs to monitor children's progress and (e) Stretch and Review, to provide teachers time to review key concepts. Included in the lessons are practice opportunities for students to collaborate with peers with teacher guidance and feedback. A manual provides scope of instruction, teaching strategies, lessons and materials.
Study: NCT05870215

Intervention type: OTHER
Intervention: Visit 1: Inflammometry
Description: Nasosorption with nasal epithelial lining fluid (NELF), nasal swab for ultrarapid SARS-CoV2 molecular test (ID NOW), nasopharyngeal swab for rapid multiplex PCR viral (BIOFIRE), nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank), chest x-ray

Intervention type: OTHER
Intervention: Visit 1: Inflammometry
Description: Nasosorption with nasal epithelial lining fluid (NELF), nasal swab for ultrarapid SARS-CoV2 molecular test (ID NOW), nasopharyngeal swab for rapid multiplex PCR viral (BIOFIRE), nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank), chest x-ray

Intervention type: OTHER
Intervention: Visit 2: Clinical exam and questionnaires
Description: Medical history and examination, including vital signs, symptom scores (ACQ-5, mMRC), visual analog scale (VAS) for six respiratory symptoms, Hospital Anxiety and Depression Scale, satisfaction questionnaire about point-of-care biomarker measurements, satisfaction questionnaire about point-of-care biomarker measurements: letter and email sent to treating doctor.
Study: NCT06257264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-68501
Description: Planned doses administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-68501
Description: Planned doses administered orally.
Study: NCT05870215

Intervention type: OTHER
Intervention: Visit 2: Respiratory physiology
Description: FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
Study: NCT04477512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Supplied by Exelixis
Study: NCT06257264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-68501
Description: Planned doses administered orally.
Study: NCT04477512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Supplied by Exelixis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Supplied by Exelixis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Supplied by Bristol-Myers Squibb
Study: NCT05870215

Intervention type: OTHER
Intervention: Visit 2: Inflammometry
Description: SARS-CoV2 Test (ID NOW), nasosorption, nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank)

Intervention type: OTHER
Intervention: Visit 3: e-mail
Description: ACQ-5, peak flow measurement, and questions about the patient's asthma management.
Study: NCT04477512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Supplied by Bristol-Myers Squibb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Supplied by Bristol-Myers Squibb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Commercially available
Study: NCT06257264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-68501
Description: Planned doses administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Standard dose administered via intramuscular injection.
Study: NCT04477512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Commercially available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Commercially available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Commercially available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Commercially available
Study: NCT05863026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)
Description: THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)
Study: NCT06257264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Standard dose administered via intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Standard dose administered via intramuscular injection.
Study: NCT04477512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Commercially available
Study: NCT05624944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 5 mg
Description: Single-dose of 5 mg of TS-142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 5 mg
Description: Single-dose of 5 mg of TS-142
Study: NCT04477512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood collection
Description: Prior to start of treatment, after 8 weeks of combination therapy, with every subsequent imaging (every 12 weeks), end of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood collection
Description: Prior to start of treatment, after 8 weeks of combination therapy, with every subsequent imaging (every 12 weeks), end of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood collection
Description: Prior to start of treatment, after 8 weeks of combination therapy, with every subsequent imaging (every 12 weeks), end of treatment
Study: NCT04744129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NN414
Description: To investigate the role of NN414 on cerebral hemodynamic in migraine patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To investigate the role of NN414 compared with saline cerebral hemodynamic in migraine patients.
Study: NCT05312892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine
Description: Moxonidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06257264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-43395
Description: Planned doses administered orally.
Study: NCT05604157

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of Tourniquet
Description: Application of tourniquet or not in adults undergoing a primary total knee replacement.
Study: NCT05624944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 5 mg
Description: Single-dose of 5 mg of TS-142
Study: NCT05806346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TXA administration
Description: Tranexamic acid intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TXA administration
Description: Tranexamic acid intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA administration
Description: Tranexamic acid intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo administration
Description: Placebo (normal saline) intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo administration
Description: Placebo (normal saline) intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo administration
Description: Placebo (normal saline) intravenous administration
Study: NCT03946462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NO gas delivered during cardiac surgery
Description: intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo gas delivered during cardiac surgery
Description: placebo blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system. The placebo gas in this study will be 21% (or atmospheric) oxygen.
Study: NCT04186286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine 4-week course
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine 4-week course
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.
Study: NCT05540665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daxdilimab
Description: Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daxdilimab
Description: Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734
Study: NCT04186286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine 4-week course
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol 4-week course
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol 4-week course
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol 4-week course
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 4-week course
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 4-week course
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 4-week course
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo
Study: NCT05341154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hcl 50Mg/Ml Inj
Description: Patients will be given the active comparator or placebo only once right before the induction of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hcl 50Mg/Ml Inj
Description: Patients will be given the active comparator or placebo only once right before the induction of anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine Hcl 50Mg/Ml Inj
Description: Patients will be given the active comparator or placebo only once right before the induction of anesthesia.
Study: NCT05540665

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal Saline)
Description: Placebo will be administered subcutaneously as two injections for each dose.
Study: NCT05704322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wim Hof Methode
Description: The intervention groups will follow a 7-weeks intervention, with one practice session per week at the rehabilitation center led by Wim Hof or one of his instructors. Besides these joint weekly sessions, the intervention groups have to practice daily at home with the Wim Hof Method app.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wim Hof Methode
Description: The intervention groups will follow a 7-weeks intervention, with one practice session per week at the rehabilitation center led by Wim Hof or one of his instructors. Besides these joint weekly sessions, the intervention groups have to practice daily at home with the Wim Hof Method app.
Study: NCT03937050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Three film-based components:~1. Professional development of doctors and nurses to improve screening and management of GDM. Modules will cover knowledge and relevant clinical guidelines, skills for glucose monitoring and managing medication, specialist obstetric care, and lifestyle counselling. The films will be screened at professional development meetings.~2. Awareness-raising among pregnant women and family members regarding GDM and the importance of healthy lifestyles during pregnancy. The film will be culturally tailored and will be screened in waiting areas of antenatal clinics/electronic versions of the films will be made available for viewing on mobile devices.~3. Structured diabetes self-management programme for women with GDM to empower them with the necessary knowledge, skills, and confidence to manage GDM successfully. The programme will incorporate behavioural counselling and educational reinforcement. Films will be screened at group sessions/viewed on mobile devices.
Study: NCT05526235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doing What Matters (DWM)
Description: The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, has been adapted for use on a smartphone or other device with internet access. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Description: PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological First Aid (PFA)
Description: PFA is a brief intervention consisting of a 15-min call that assess the immediate concerns and needs of an individual in order to connect individuals to help and resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological First Aid (PFA)
Description: PFA is a brief intervention consisting of a 15-min call that assess the immediate concerns and needs of an individual in order to connect individuals to help and resources.
Study: NCT06035237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Spray
Description: Cold Spray: Cold sprays, composed of liquefied gases under high pressure, rapidly evaporate from the applied area, causing a sudden drop in skin temperature. This condition leads to the temporary desensitization of pain receptors or the activation of ion channels, resulting in the brief alleviation of pain sensation. Various medical, non-medical, and surgical methods are employed to manage pain. Cold sprays are among non-medical methods, including massage, cold application, and distraction techniques. Therefore, cold sprays cannot be prescribed like medication. They are used for local anesthesia in cases of acute trauma, injections, blood collection, vein puncture, and similar situations.
Study: NCT05983250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNX-103
Description: oral levosimendan 1 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05995054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab Injection [Gazyva]
Description: intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 110 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment.
Study: NCT05255549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESWT + Stretching
Description: 3 weeks intervention:~* 3 sessions of ESWT, once a week~* 6 sessions of passive stretching, twice a week

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ESWT and SHAM + Stretching
Description: 3 weeks intervention:~* 1 sessions of ESWT + 2 sessions of Sham, once a week~* 6 sessions of passive stretching, twice a week
Study: NCT06278090

Intervention type: DRUG
Intervention: Ursodeoxycholic Acid Only Product
Description: Ursodeoxycholic acid treatment, 10-15mg/kg/day for at least 6 months